semaglutide and osteoporosis Weight loss induced bone loss: mechanism of action clinical implications Semaglutide does more good things-

doi: 10.3389/fcell.2025.1633166 Received 22 May 2025 Accepted 14 August 2025 Published 29 August 2025 Volume 13 - 2025 Edited by Asok K

research into the role of the gut microbiome is at an early stage and is not yet used clinically to guide treatment decisions Adherence to treatment: Missing doses or inconsistent injection timing may reduce efficacy Concurrent medicines: As a class effect, GLP-1 receptor agonists slow gastric emptying, which may affect the absorption timing of some oral medicines

Some individuals with Hashimoto's disease develop metabolic syndrome or type 2 diabetes, further complicating weight management efforts

Dose changes depend on how you feel, appetite changes, and weight stability